Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 9/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3288310 | 1.00 | SLC9A1 (0.68) | SLC9A1MAPTKMT2AKDM1AMAOA | |
| SCHEMBL3288307 | 1.00 | SLC9A1 (0.68) | SLC9A1MAPTKMT2AKDM1AMAOA | |
| Bicarbonate SCHEMBL3663569 | 0.93 | SLC9A1 (0.60) | SLC9A1MAPTKMT2AKDM1AMAOA | |
| Bicarbonate SCHEMBL3663565 | 0.93 | SLC9A1 (0.60) | SLC9A1MAPTKMT2AKDM1AMAOA | |
| Bicarbonate SCHEMBL3663566 | 0.93 | SLC9A1 (0.60) | SLC9A1MAPTKMT2AKDM1AMAOA | |
| SCHEMBL18927360 | 0.84 | SLC9A1 (0.62) | SLC9A1MAPTKMT2ALMNACYP1A2 | |
| SCHEMBL16819920 | 0.84 | SLC9A1 (0.62) | SLC9A1MAPTKMT2ALMNACYP1A2 | |
| SCHEMBL3287837 | 0.84 | SLC9A1 (0.62) | SLC9A1MAPTKMT2ALMNACYP1A2 | |
| SCHEMBL3287845 | 0.84 | SLC9A1 (0.62) | SLC9A1MAPTKMT2ALMNACYP1A2 | |
| SCHEMBL3655655 | 0.84 | SLC9A1 (0.62) | SLC9A1MAPTKMT2ALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103373911-B | Single fluoro cyclopropanes compound and its preparation method and application | 中国科学院上海有机化学研究所 | 2016-12-14 | — | — | CN | disclosed |
| CN-104884432-A | Alpha7 nicotinic acetylcholine receptor modulators and uses thereof-I | MERCK SHARP & DOHME | 2015-09-02 | — | — | CN | disclosed |
| CN-101495444-B | A process for the preparation of optically active cyclopropylamines | ASTRAZENECA SWEDEN AB | 2015-02-04 | — | — | CN | disclosed |
| CN-104119246-A | Cyclopropane derivatives, and preparation method and application thereof | SHANGHAI INST ORGANIC CHEM | 2014-10-29 | — | — | CN | disclosed |
| EP-2207540-B1 | CYCLOPROPYL ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2014-02-26 | — | — | EP | disclosed |
| EP-2207540-B1 | CYCLOPROPYL ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2014-02-26 | — | — | EP | disclosed |
| CN-103373911-A | Monofluorocyclopropane compounds as well as preparation method and application for same | SHANGHAI INST ORGANIC CHEM | 2013-10-30 | — | — | CN | disclosed |
| EP-2644591-A1 | Optically active 2-aryl cyclopropane carboxamide intermediates | Astrazeneca AB (SE) | 2013-10-02 | — | — | EP | disclosed |
| CN-101815512-B | Cyclopropyl aryl amide derivatives and uses thereof | HOFFMANN LA ROCHE | 2013-04-24 | — | — | CN | disclosed |
| US-8278475-B2 | Processes for the preparation of optically active intermediates | ASTRAZENECA AB (SE) | 2012-10-02 | — | — | US | disclosed |
| US-7723391-B2 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723391-B2 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-05-25 | — | — | US | disclosed |
| CN-101495444-A | A process for the preparation of optically active cyclopropylamines | ASTRAZENECA AB (SE) | 2009-07-29 | — | — | CN | disclosed |
| EP-2049463-A1 | A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CYCLOPROPYLAMINES | Astra Zeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
| WO-2009043784-A1 | CYCLOPROPYL ARYL AMIDE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| US-20080071114-A1 | Processes For The Preparation Of Optically Active Intermediates | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | US | disclosed |
| WO-2008018823-A1 | A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CYCLOPROPYLAMINES | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080071114-A1 | Processes For The Preparation Of Optically Active Intermediates | DHPS, CYP1B1, CYP2S1 | SLC9A1 4551/4885MAPT 2852/4885KMT2A 3608/4885 |
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | AR, ADRA2A, ADRA1A | SLC9A1 3094/4885MAPT 2449/4885KMT2A 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.